Interview with Esther Lim, Managing Partner, Finnegan
Finnegan is a leader and expert on the topic of intellectual property and it entered Asia in the late 1980s with an office in Tokyo yet China only very recently.…
Address: Mirae Asset Tower 28/F, Unit A-B No. 166 Lujiazui Ring Road, Pudong Shanghai, China 200120,China
Tel: 86 21 6194 2000
Web: http://www.finnegan.com/en-US/locations/region.aspx?region=5
Finnegan has more than 40 years of experience in successfully navigating U.S. IP law. Finnegan works with clients of all sizes, from virtually every industry and technology to identify, protect, advocate, and leverage their most valuable IP assets. Finnegan guides U.S. organizations as well as multinational entities that wish to conduct business in the U.S. Foreign innovators entering the U.S. market are often surprised at the intricacies of the intellectual property legal system. Patent law is becoming increasingly complex, with regulatory and legislative changes having a dramatic impact on companies’ intellectual property and business strategies. Finnegan views this complexity as an opportunity to think creatively. Finnegan’s full range of IP experience—from idea protection and management to litigation and appeals—gives the company the perspective to anticipate potential issues and devise creative solutions.
Asia boasts some of the world’s most sophisticated markets and fastest growing economies. Innovative corporations and organizations across Asia turn to Finnegan to identify, protect, advocate, and leverage their most valuable IP assets. To meet the needs of Finnegan’s Asian clients conducting business in their headquarter countries or in the United States, Finnegan has established offices in Shanghai, Taipei, and Tokyo. The firm also has strong ties to the IP legal communities in Korea and India, and our attorneys regularly travel to these countries to speak at conferences and meet with clients.
Finnegan’s licensed Foreign Representative Office in China is located in the Pudong area of Shanghai, and Finnegan’s attorneys are able to serve clients anywhere in the greater China region. As Chinese companies continue to expand their markets, Finnegan is on the ground to assist them with their U.S. IP strategies and needs.
Finnegan is proud to have been active and involved in the Chinese community for many years. We have over 30 professionals who speak Chinese, many with degrees from Chinese universities. Our local outreach efforts have included seminars, educational programs, and roundtable discussions for both business groups and universities. We are particularly active in U.S. IP licensing matters in China.
Intellectual Property Law
Finnegan is a leader and expert on the topic of intellectual property and it entered Asia in the late 1980s with an office in Tokyo yet China only very recently.…
The partnership between global pharma giant Eli Lilly and Chinese biotech Innovent Biologics, first initiated in March 2015, continues to bear dividends for both parties. The recent announcement that Lillly…
Dr Kerry Blanchard explains why he took on the challenge of becoming CEO of Chinese biotech Everest Medicines and how Everest’s internationalist approach to teambuilding helps it stand out from…
Founded in 2009 by CEO Dr XU Ting, Alphamab started its journey as a protein engineering company with the ultimate dream of becoming, as many Chinese biotechs aspire, a global…
Since the Chinese government unrolled an unprecedented volume-based procurement initiative for essential drugs used in the public hospital system in November 2018 in a bid to curb unsustainable healthcare expenditures,…
A roundup of the latest news from Chinese pharma, including Big Pharma players losing out in the latest round of domestic procurement bidding, updates on Sinopharm’s experimental COVID-19 vaccine, biotech…
The only company in our Summer 2020 edition of InFocus: 5 Biotechs to Watch in China to be helmed by a non-founding CEO, I-Mab Biopharma has advanced since its establishment…
Dr Zaiqi Wang, chairman and CEO of Chinese oncology biotech InxMed, highlights the vital importance of combination therapies in cancer treatment, assesses the level of innovation in China, and outlines…
It has been just over two years since the Hong Kong Stock Exchange (HKEX) revised its listing rules to allow pre-revenue biotechs to IPO as long as they met certain…
Probably one of the most recognisable Chinese biotechs globally, Zai Lab may only be seven years old but the company has progressed rapidly in becoming a NASDAQ-listed company with not…
On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech companies. Nearly 2.5 years later, 20 companies…
A roundup of latest news from Chinese pharma and biotech, including a record high share price for Hansoh, strategic healthcare partnerships, venture capital gains, and recent IPO news from Sunshine…
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s…
See our Cookie Privacy Policy Here
